Hong Kong Airlines Stock News

SEHK:3692
SEHK:3692Pharmaceuticals

How Investors Are Reacting To Hansoh Pharmaceutical Group (SEHK:3692) Phase III Psoriasis Trial Success

Hansoh Pharmaceutical Group reported that HS-10374, its self-developed selective TYK2 inhibitor, met co-primary and multiple secondary endpoints in a pivotal Phase III trial in adults with moderate-to-severe plaque psoriasis. The trial showed higher PASI 75 and sPGA 0/1 response rates than placebo, no new safety signals, and the company now plans to prepare a new drug application in China. The psoriasis data indicate that HS-10374 could extend Hansoh Pharmaceutical Group's reach into chronic...
SEHK:6869
SEHK:6869Communications

How Investors May Respond To YOFC Stock After Interim Dividend Approval

Yangtze Optical Fibre And Cable Joint Stock Limited Company approved an interim dividend of RMB 10.60 per 10 shares for the first half of 2026, totaling about RMB 877,579,414, with H share holders generally receiving HKD 12.26 per 10 shares based on a fixed exchange rate calculation. The detailed dividend structure, including currency conversion terms and a defined entitlement date, highlights how Yangtze Optical Fibre And Cable manages capital returns between domestic and H share...
SEHK:1898
SEHK:1898Oil and Gas

Is China Coal Energy (SEHK:1898) A Bargain As Coal Volumes Slip?

China Coal Energy (SEHK:1898) came back into focus after its September 11 update showed lower year on year commercial coal and self produced coal volumes, while several chemical product lines reported higher monthly and year to date tonnages. Recent trading shows that China Coal Energy’s share price has drifted over the past month and quarter, with a 30 day share price return of 3.22% lower and a 90 day share price return of 1.19% lower. This comes even as the year to date share price return...
SEHK:2380
SEHK:2380Renewable Energy

What China Power International Development Stock's Environmental Services Deal Means For Shareholders

China Power International Development entered into a multi year Framework Agreement with State Power Investment Corporation Limited Group in September 2026 to supply environmental protection engineering services and related products, with proposed annual caps of RMB 700,000,000 for late 2026 and RMB 1,450,000,000 for 2027 and 2028. The agreement formalizes a broad service scope from coal fired plant upgrades to carbon capture projects. This indicates that environmental services are becoming...
SEHK:1398
SEHK:1398Banks

Industrial And Commercial Bank Of China (SEHK:1398) Just Gave Investors Something To Weigh

Industrial and Commercial Bank of China (SEHK:1398) just wrapped up a RMB 20b issuance of undated Additional Tier 1 capital bonds, giving the lender fresh regulatory capital and added financial flexibility. The fresh Additional Tier 1 capital comes as Industrial and Commercial Bank of China’s HK$7.58 share price sits on a year to date share price return of 19.56%, with a 90 day share price gain of 8.91% and a 1 year total shareholder return of 39.24%. This hints that investors have been...
SEHK:2016
SEHK:2016Banks

China Zheshang Bank (SEHK:2016) Could Be 64% Below Fair Value On XTransfer Deal

XTransfer’s new cooperation with China Zheshang Bank (SEHK:2016) on all currency settlement and minor currency collection puts cross border payment plumbing at center stage for anyone tracking the stock. The cooperation lands while China Zheshang Bank’s 30 day share price return of 6.78% and 90 day share price return of 6.09% point to improving short term momentum, even though the year to date share price return declined 3.56% and the 1 year total shareholder return declined 1.48%. This...
SEHK:1548
SEHK:1548Life Sciences

Genscript Stock In Focus After TuneLab Alliance With Eli Lilly

Genscript Biotech announced that it joined Eli Lilly's TuneLab AI-enabled drug discovery platform, agreeing to provide preferred-rate wet lab services that turn AI predictions into biological data, in line with its integrated R&D support strategy. The TuneLab agreement embeds Genscript Biotech directly into AI-driven discovery workflows, which could influence future demand, capacity planning, and pricing power across its lab services portfolio. We will now assess how Genscript Biotech's...
SEHK:3738
SEHK:3738Software

Why Vobile Group Stock Is In Focus After SeeBay Launch

Vobile Group officially launched the SeeBay platform on 17 September 2026, positioning it as a one stop hub for AI content creation and global IP monetization, with over 20,000 registered users and more than 13,600 content creation tasks recorded so far. The collaboration agreement between a Vobile Group subsidiary and Ant Blockchain Technology to build a copyright large model signals a push to hardwire IP protection and rights management into AI driven content workflows. This development...
SEHK:467
SEHK:467Oil and Gas

United Energy Group (SEHK:467) Shares Just Moved, So What Is Going On?

Index Exit Puts United Energy Group in Focus United Energy Group (SEHK:467) has been removed from the FTSE All-World Index in its USD version, an index change that can affect passive fund flows and institutional visibility. United Energy Group’s HK$0.42 share price has moved higher over the past month, with a 30-day share price return of 9.09% and a 90-day gain of 16.67%. However, the year-to-date share price return is down 10.64% and the 1-year total shareholder return has fallen 22.22%...
SEHK:551
SEHK:551Luxury

Is Yue Yuen Industrial (Holdings) (SEHK:551) Cheap Following Its Latest Revenue Update?

Yue Yuen Industrial (Holdings) (SEHK:551) has reported unaudited figures for August, with net consolidated operating revenue of US$636.647m for the month and US$5.217b for the year to date. The latest revenue update lands as Yue Yuen Industrial (Holdings) trades at HK$12.4, with the share price down 10.6% over the past 30 days and 22.35% year to date, even though the 3 year total shareholder return of 78.57% points to a much stronger longer run outcome than the recent pullback...
SEHK:1113
SEHK:1113Real Estate

CK Asset Holdings (SEHK:1113) Could Be 14% Undervalued After Settling At HK$46

CK Asset Holdings (SEHK:1113) has attracted fresh attention after its recent close at HK$46. The move comes against a backdrop of mixed short term returns and double digit gains over the past year. Short term momentum for CK Asset Holdings has cooled, with the share price down over the past week and month. However, the 90 day share price return remains in positive territory and a 1 year total shareholder return of 29.92% still point to stronger longer term gains. Scan beyond CK Asset Holdings...
SEHK:6808
SEHK:6808Consumer Retailing

Sun Art Retail Group (SEHK:6808) Following FTSE Exit Still Looks Undervalued

Sun Art Retail Group (SEHK:6808) was recently removed from the FTSE All-World Index, a move that can prompt forced selling by index-tracking funds and reshape how investors view liquidity and visibility. Recent share price performance around HK$1.06 has been choppy, with a 1-day share price return of 2.91% and a 90-day share price return of 3.92%. However, the year-to-date share price return has fallen 39.08% and the 1-year total shareholder return is down 40.09%. This points to fading...
SEHK:2285
SEHK:2285Consumer Durables

Chervon Holdings (SEHK:2285) Gets A New CEO After A Sharp Rally But Still Looks Pricey

Chervon Holdings (SEHK:2285) just made a sweeping leadership change that puts long time power tool executive Joseph Galli Jr. in the CEO seat, with Jeffrey P. Campbell stepping in to guide industrial and commercial sales. The leadership reshuffle comes at a time when Chervon Holdings’ shares have picked up momentum, with a 30 day share price return of 23.53% and a 90 day gain of 57.50% from a latest close of HK$25.2. The 1 year total shareholder return of 16.53% points to a more measured...
SEHK:1177
SEHK:1177Pharmaceuticals

Could Oral STAT6 Data Change The Case For Sino Biopharmaceutical Stock

Sino Biopharmaceutical presented preclinical data for TQH5528, an oral STAT6 degrader from its OAPD platform, at the European Respiratory Society 2026 Congress. The data highlighted activity on the IL-4/IL-13/STAT6 axis and convenient oral dosing potential versus injectable biologics. The program features a novel CRBN ligand, picomolar STAT6 degradation and favourable oral exposure across species. Taken together, these attributes point to meaningful R&D investment around a differentiated...
SEHK:2268
SEHK:2268Life Sciences

WuXi XDC Cayman (SEHK:2268) Climbed, What Is Behind The Fresh Attention?

WuXi XDC Cayman (SEHK:2268) is back in focus after announcing an exclusive global out licensing deal with Ona Therapeutics for its WuXiTecan-2 payload linker technology platform. The licensing update comes on top of a strong run in WuXi XDC Cayman’s stock. The latest share price is HK$80.7 after a 1-day share price return of 4.81% and a 90-day share price return of 65.17%. This performance far outpaces its 1-year total shareholder return of 5.84%, suggesting that momentum has picked up...
SEHK:1093
SEHK:1093Pharmaceuticals

CSPC Pharmaceutical Group (SEHK:1093) Expands Its Pipeline, Is The Stock Still Undervalued?

CSPC Pharmaceutical Group (SEHK:1093) has been busy. A fresh Phase II trial in type 2 diabetes, new NMPA designations in oncology and multiple trial approvals across neurology and ophthalmology are drawing fresh attention to the shares. The recent cluster of diabetes, oncology, neurology and ophthalmology updates appears to have coincided with a sharp pickup in interest. CSPC Pharmaceutical Group’s 1-day share price return of 7.56% at HK$9.605 capped a 90-day share price return of 40.42%,...
SEHK:1164
SEHK:1164Oil and Gas

Index Inclusion Could Be A Big Moment For CGN Mining Stock (SEHK:1164)

CGN Mining Company Limited has been added to the Hang Seng China Affiliated Corporations Index, placing the uranium trader alongside other China related corporates that the benchmark tracks. The inclusion in this index can draw more attention from institutional funds that track or reference it, which may affect how CGN Mining’s relatively high P/E valuation is viewed against peers. The next area of focus will be how CGN Mining’s new index inclusion could reshape its broader investment...
SEHK:2419
SEHK:2419Food

Are August Sales Altering The Investment Case For Dekon Food and Agriculture Group (SEHK:2419)?

Dekon Food and Agriculture Group reported unaudited August 2026 sales, including 935,030 market hogs with revenue of RMB 1,325.46 million and 6,757,230 yellow-feathered broilers with revenue of RMB 237.63 million, alongside year-to-date hog revenue of RMB 10,740.15 million and broiler revenue of RMB 1,661.08 million. The disclosure gives investors a granular view of Dekon Food and Agriculture Group’s hog and poultry scale, highlighting reliance on two core livestock streams and the breadth...
SEHK:9615
SEHK:9615Machinery

Mech Mind Robotics Technologies (SEHK:9615) Slides On Rich Sales Multiple, Is The Premium Still Justified?

Mech-Mind Robotics Technologies (SEHK:9615) has drawn fresh attention after a recent slide in its share price, with the stock down 1.5% on the day and roughly 4.1% over the past week. For Mech-Mind Robotics Technologies, that pullback sits on top of a weaker backdrop, with the share price return down 19.54% year to date and the latest drop hinting that short term momentum is fading as investors reassess both growth potential and risk. Scan how Mech-Mind Robotics Technologies compares with...
SEHK:165
SEHK:165Capital Markets

China Everbright (SEHK:165) Moved Higher, What Is Drawing Attention Now?

China Everbright (SEHK:165) has been dropped from the FTSE All-World Index (USD). This type of change often prompts mechanical selling as index-tracking funds and benchmarked investors adjust positions. Recent trading has been choppy for China Everbright. The share price has climbed over the short term, with a 10.14% 30 day share price return and 14.50% over 90 days. However, the year to date share price return is down 33.11% and the 1 year total shareholder return has fallen 28.66%, while...
SEHK:316
SEHK:316Shipping

Orient Overseas International (SEHK:316) Faces A 13% Premium Following Its Recent Pullback

Orient Overseas (International) (SEHK:316) has drawn fresh attention after recent trading left the share price at HK$146.30. These short term moves contrast sharply with the performance over the past 3 years. For context, Orient Overseas (International) has seen a sharp 30-day share price return of down 17.2%, even though the 90-day share price return is up 19.7%. Meanwhile, the 3-year total shareholder return of 73.9% and 5-year total shareholder return of 127.8% show a much stronger longer...
SEHK:1952
SEHK:1952Biotechs

3 Chinese Biopharma Stocks Retail Investors Are Watching For Licensing Deals

Chinese biopharma developers just caught a rare break. Fresh signals from Washington suggest U.S. pharma groups may keep licensing most drugs from Chinese partners, and the Hang Seng Biotech Index has already reacted. This keeps the door open for cross-border deals that can reshape how companies fund pipelines and share risk. This article walks through three Chinese biopharma stocks exposed to this news and why that matters for your portfolio decisions. The stocks covered below are just a...
SEHK:2228
SEHK:2228Life Sciences

Stanford Drug Discovery Deal Could Shape The Case For XtalPi Holdings Stock

On 17 September 2026, XtalPi Holdings announced that subsidiary LCC Technologies entered a drug discovery collaboration with Stanford University, pairing Stanford’s disease biology research with LCC’s AI-driven PACE platform for small molecule development across multiple disease areas. The agreement creates a joint steering committee that screens Stanford investigators’ proposals and directs LCC’s automated discovery resources toward the projects with the strongest scientific rationale and...
SEHK:1672
SEHK:1672Biotechs

Ascletis Pharma (SEHK:1672) Starts U.S. Obesity Trial As Valuation Looks About Right

Ascletis Pharma (SEHK:1672) has kicked off a U.S. Phase I trial for ASC36 oral tablets for obesity treatment, following recent FDA Investigational New Drug clearance that advances the obesity pipeline into human testing. Ascletis Pharma’s latest obesity trial news hit as the HK$8.97 share price jumped with a 1-day share price return of 10.13%. However, the 30-day share price return is down 10.48% and the year-to-date share price return is down 22.14%, while the 3-year total shareholder return...